GUJTHEMBSEGUJARAT THEMIS BIOSYN LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Tue, 25 Aug, 2026 · 21:34 IST

Gujarat Themis Biosyn FY26 audited results filed, clean audit opinion

Related Party TransactionsResults View source PDFExplain this filing

GUJTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+3.3%Reaction day
₹407.00
prior close
₹401.75
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+0.6%+2.7% vs market
Pharmaceuticals peers, median of 175sector+0.3%+3.0% vs sector

On the reaction day the stock moved 2.7 pts more than Nifty Microcap 250 and 3.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+0.9
10m
+2.5
15m
+1.6
30m
+3.5
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+3.3+0.6+2.7+0.3+3.0
Next day
+1.4+0.4+1.0+0.4+1.0
2d
+0.7+0.7+0.1+0.7+0.0
3d
+3.4+1.0+2.4+0.8+2.6
4d
+3.2-0.0+3.2+0.5+2.7
5d
+1.6-0.6+2.2+0.6+0.9
1w
+1.2+0.7+0.5+1.1+0.0
15d
+3.0-1.2+4.2+0.9+2.1
1m
-2.1-0.9-1.2-0.5-1.6
2m
-17.1-9.0-8.2-5.8-11.4
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 175Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gujarat Themis Biosyn filed audited FY26 results (year ended March 31, 2026). Auditor GMJ & Co gave an unqualified opinion with no qualifications or going concern issues. Revenue rose to INR 16,582.28 lakhs from INR 15,079.99 lakhs, about 10 percent growth. Total assets jumped to INR 50,342.66 lakhs from INR 30,131.25 lakhs as capital work-in-progress was capitalized into PPE. Borrowings rose sharply to INR 15,986 lakhs. Results pending shareholder approval at AGM.

Likely market impact

Clean audit and 10 percent revenue growth are positives. Big jump in borrowings and depreciation signals heavy capex that may pressure margins.